Natco Pharma Ltd (Natco Pharma) is a vertically integrated pharmaceutical company, which develops, manufactures and markets finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs), which include niche and technically complex molecules.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D efforts focus on developing novel molecules and improving the processes along with new delivery systems in collaboration with multinational companies and established research organizations and universities. In FY2023, the company spent INR892 million on its R&D activities, which as a percentage of revenue stood at 3.3%. It owns nine manufacturing facilities in India and two research centers in Telangana. - In the US, the company’s R&D focuses on molecules with complex chemistry, which have fewer players to compete with. - It has patents granted in India and International markets in the areas of new chemical entities, API – process, finished dosage products, natural products and design. The company has filed six international and 18 Indian patents; eight international patents and two Indian patents were granted during the year. - As of March 31, 2023, the company’s major pipeline products included Eliquis (Apixaban) for anticoagulant; Kyprolis (carfilzomib) for multiple myeloma; Lynparza (Olaparib) for ovarian/breast cancer; Pomalyst (pomalidomide) for multiple myeloma; Imbruvica (Ibrutinib) for leukemia; Lonsurf (trifluridine/tipiracil) for metastatic colorectal cancer; Yondelis (Trabectedin) for advanced soft-tissue sarcoma/ovarian cancer; Calquence (Acalabrutinib) for blood cancer; Ozempic (Semaglutide pen) for diabetes and Zydelig (Idelalisib) for cancer.